Will Pfizer, which acquired Messera, begin competing with Vigovi and Maunjaro in the weight-loss drug market?

today Messera, an obesity treatment candidate acquired by Pfizer Dominating the weight loss drug market with Wigobi, Maunjaro Let me summarize the story.

 

What is Messiah?

 

Metsera was originally under development by an independent pharmaceutical company. It is a new drug candidate for the treatment of obesity.
Pfizer to acquire Messera in 2025 A major change is expected in the global diet pill market.

 

Just like Wigobina Maunjaro GLP-1 They are known as a family, and it is expected that side effects will be reduced through differences in their mechanisms of action.

 

 

Wegobi effects, price, and side effects

 

Wegovy is a drug developed by Novo Nordisk, and has shown excellent effects in suppressing appetite and losing weight.

It's pretty famous in Korea now,

 

The Wegobi effect Average weight loss of 15% or more It has been proven.

However, the price of the Wigobi is a burden, ranging from 230,000 won to 390,000 won depending on the capacity.

 

Also, the representative side effects of Wegobi include nausea, vomiting, and constipation.

 

 

Maunjaro effects, price, and side effects

Mounjaro It is a GLP-1+GIP dual agonist developed by Eli Lilly and has a more powerful weight loss effect than Wegobi.

 

The effects of Maunjaro are known to include up to 20% weight loss and improved blood sugar levels.

It was released in Korea a while ago.

The price of Maunjaro is approximately 290,000 won for 2.5 mg and 380,000 won for 5 mg.

 

Side effects reported with Maunjaro include indigestion, loss of appetite, and pain at the injection site.

 

 

Messera vs. Wigobi vs. Maunjaro

- Wegobi: Market leader, proven effective, but burdened by price and side effects.
- Maunjaro: Powerful weight loss effect, can even improve blood sugar levels, and is also expensive.
- Messera: New drug candidate, accelerated development through Pfizer acquisition, likely to have relatively fewer side effects.

 

Although clinical data on Messera are still limited, Pfizer's capital and research network make it highly likely that it will enter the market quickly.

 

 

Weight Loss Drug Market Outlook

Experts say Obesity treatment market It is expected that we will enter a full-scale competitive landscape after 2026.

Not only does it have a weight loss effect, Price competitiveness, side effects, and insurance coverage will be a key factor in consumer choice.

 

 

Messiah It will be interesting to see what position Ga will occupy between Wigobi and Maunjaro.

 

 

FAQ

 

✅Q1. When can I get Messera?

Because it is still in the clinical phase, general prescriptions are not available. The launch date will be determined based on clinical trial results after Pfizer completes the acquisition.

 

✅Q2. How much does Wegobi cost?

Currently, the price at domestic pharmacies ranges from about 230,000 won to 390,000 won depending on the dosage.

 

✅Q3. How much does a mount cost?

Depending on the capacity, the price of a Maunjaro is set at 290,000 to 380,000 won.

 

✅Q4. What are the side effects of Wegobi and Maunjaro?

The most common side effects of Wegobi include nausea, vomiting, and constipation, while the most common side effects of Maunjaro include indigestion, loss of appetite, and pain at the injection site.

 

✅Q5. Is it possible to apply for weight loss medication insurance?

Currently, it's difficult to obtain insurance coverage for obesity treatment alone in Korea. However, in cases with a clear treatment goal, such as for diabetes, limited coverage is possible.

 

 

See more related articles??

💉 Compare the price and salary of Maunjaro with the Wegobi

💉 From side effects of WegoPro to reviews of products purchased with my own money and essential information